Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy Study of Deferiprone in PKAN
2014-001427-79Phase 3Completed
- Sponsor
- ApoPharma Inc.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deferiprone in pantothenate kinase-associated neurodegeneration (PKAN), sponsored by ApoPharma Inc. Primary endpoint: Adverse events. Started Mar 2015; status: completed.
02
Drugs
deferiprone
03
Conditions
pantothenate kinase-associated neurodegeneration (PKAN)
Beyond the preview
Go deeper on 2014-001427-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001427-79.